GSK : FDA Approves Nucala As Add-on Maintenance Treatment For Chronic Obstructive Pulmonary Disease
23/5 04:10
(RTTNews) - GSK plc. (GSK, GSK.L) announced that the US Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype....